Daridorexant

Major

Daridorexant Acetaminophen And Codeine Capital® & Codeine Explained An increased risk CNS depression Details Daridorexant Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure Details Daridorexant Buprenorphine Belbuca Explained An increased risk CNS depression Details Daridorexant Relugolix Orgovyx Explained Increased relugolix exposure Details Daridorexant Colchicine Colcrys Explained Increased CYP3A4/P-gp with NTI substrate exposure and an increased risk of CYP3A4/P-gp with NTI substrate-related adverse effects Details Daridorexant Abemaciclib Verzenio Explained Increased CYP3A4 substrate with NTI exposure Details Daridorexant Acalabrutinib Calquence Increased CYP3A4 substrate with NTI exposure Details Daridorexant Aripiprazole Injection Abilify An increased risk CNS depression Details Daridorexant Asenapine Transdermal Patch Secuado An increased risk CNS depression Details Daridorexant Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure Details Daridorexant Bosutinib Bosulif Increased CYP3A4 substrate with NTI exposure Details Daridorexant Brigatinib Alunbrig Increased CYP3A4 substrate with NTI exposure Details Daridorexant Butorphanol Injection Butorphic An increased risk CNS depression Details Daridorexant Butorphanol Nasal Spray Stadol® NS An increased risk CNS depression Details Daridorexant Cetirizine Injection Aller-Tec An increased risk CNS depression Details Daridorexant Cetirizine Ophthalmic Zerviate An increased risk CNS depression Details Daridorexant Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure Details Daridorexant Clindamycin Topical C/T/S® Increased CYP3A4 substrate with NTI exposure Details Daridorexant Clindamycin Vaginal Cleocin Increased CYP3A4 substrate with NTI exposure Details Daridorexant Cobimetinib Cotellic Increased CYP3A4 substrate with NTI exposure Details Daridorexant Cyclosporine Injection Atopica Increased daridorexant and cycloSPORINE exposure Details Daridorexant Cyclosporine Ophthalmic Cequa Increased daridorexant and cycloSPORINE exposure Details Daridorexant Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Daridorexant Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Daridorexant Dasatinib Phyrago Increased CYP3A4 substrate with NTI exposure Details Daridorexant Diazepam Nasal Spray Valtoco An increased risk CNS depression Details Daridorexant Diazepam Rectal Diastat An increased risk CNS depression Details Daridorexant Digoxin Cardoxin® Increased digoxin exposure Details Daridorexant Dihydroergotamine Injection DHE-45® Injection Increased CYP3A4 substrate with NTI exposure Details Daridorexant Dihydroergotamine Nasal Spray Migranal Increased CYP3A4 substrate with NTI exposure Details Daridorexant Diphenhydramine Injection Banophen An increased risk CNS depression Details Daridorexant Diphenhydramine Topical Afterbite with Antihistamine An increased risk CNS depression Details Daridorexant Docetaxel Beizray Increased CYP3A4 substrate with NTI exposure Details Daridorexant Docetaxel Injection Beizray Increased CYP3A4 substrate with NTI exposure Details Daridorexant Dofetilide Tikosyn Increased CYP3A4 substrate with NTI exposure Details Daridorexant Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Daridorexant Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Daridorexant Entrectinib Rozlytrek Increased CYP3A4 substrate with NTI exposure Details Daridorexant Esketamine Nasal Spray Spravato An increased risk CNS depression Details Daridorexant Everolimus Afinitor Increased CYP3A4/P-gp with NTI substrate exposure and an increased risk of CYP3A4/P-gp with NTI substrate-related adverse effects Details